Panagiota-Efstathia Nikolaou PhD, Lara S.F. Konijnenberg MD PhD, Ioannis V. Kostopoulos PhD, Marios Miliotis PhD, Nikolaos Mylonas MSc, Anastasios Georgoulis PhD, George Pavlidis MD PhD, Carolien T.A. Kuster Msc, Vince P.A. van Reijmersdal Msc, Tom T.J. Luiken Msc, Anna Agapaki PhD, Rona Roverts PhD, Nikolaos Orologas PhD, Dimitris Grigoriadis PhD, Gaëtan Pallot PhD, Pierre Boucher MSc, Nikolaos Kostomitsopoulos PhD, Michael Paul Pieper PhD, Stéphane Germain PhD, Yannis Loukas PhD, Yannis Dotsikas PhD, Ignatios Ikonomidis MD PhD, Artemis G. Hatzigeorgiou PhD, Ourania Tsitsilonis MD PhD, Coert J. Zuurbier PhD, Robin Nijveldt MD PhD, Niels van Royen MD PhD, Ioanna Andreadou PhD
{"title":"恩格列净治疗急性心肌梗死可通过预防内皮损伤减少无回流并保护心功能","authors":"Panagiota-Efstathia Nikolaou PhD, Lara S.F. Konijnenberg MD PhD, Ioannis V. Kostopoulos PhD, Marios Miliotis PhD, Nikolaos Mylonas MSc, Anastasios Georgoulis PhD, George Pavlidis MD PhD, Carolien T.A. Kuster Msc, Vince P.A. van Reijmersdal Msc, Tom T.J. Luiken Msc, Anna Agapaki PhD, Rona Roverts PhD, Nikolaos Orologas PhD, Dimitris Grigoriadis PhD, Gaëtan Pallot PhD, Pierre Boucher MSc, Nikolaos Kostomitsopoulos PhD, Michael Paul Pieper PhD, Stéphane Germain PhD, Yannis Loukas PhD, Yannis Dotsikas PhD, Ignatios Ikonomidis MD PhD, Artemis G. Hatzigeorgiou PhD, Ourania Tsitsilonis MD PhD, Coert J. Zuurbier PhD, Robin Nijveldt MD PhD, Niels van Royen MD PhD, Ioanna Andreadou PhD","doi":"10.1016/j.jacbts.2024.08.003","DOIUrl":null,"url":null,"abstract":"Empagliflozin treatment before acute myocardial infarction mainly targets the endothelial cell transcriptome. Empagliflozin treatment before and after myocardial infarction decreased no reflow and microvascular injury, leading to reduced infiltration of inflammatory cells, reduced infarct size, and improved cardiac function in mice. In diabetic patients receiving empagliflozin after myocardial infarction, perfused boundary region, flow-mediated dilation, and global longitudinal strain were improved.","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":null,"pages":null},"PeriodicalIF":8.4000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage\",\"authors\":\"Panagiota-Efstathia Nikolaou PhD, Lara S.F. Konijnenberg MD PhD, Ioannis V. Kostopoulos PhD, Marios Miliotis PhD, Nikolaos Mylonas MSc, Anastasios Georgoulis PhD, George Pavlidis MD PhD, Carolien T.A. Kuster Msc, Vince P.A. van Reijmersdal Msc, Tom T.J. Luiken Msc, Anna Agapaki PhD, Rona Roverts PhD, Nikolaos Orologas PhD, Dimitris Grigoriadis PhD, Gaëtan Pallot PhD, Pierre Boucher MSc, Nikolaos Kostomitsopoulos PhD, Michael Paul Pieper PhD, Stéphane Germain PhD, Yannis Loukas PhD, Yannis Dotsikas PhD, Ignatios Ikonomidis MD PhD, Artemis G. Hatzigeorgiou PhD, Ourania Tsitsilonis MD PhD, Coert J. Zuurbier PhD, Robin Nijveldt MD PhD, Niels van Royen MD PhD, Ioanna Andreadou PhD\",\"doi\":\"10.1016/j.jacbts.2024.08.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Empagliflozin treatment before acute myocardial infarction mainly targets the endothelial cell transcriptome. Empagliflozin treatment before and after myocardial infarction decreased no reflow and microvascular injury, leading to reduced infiltration of inflammatory cells, reduced infarct size, and improved cardiac function in mice. In diabetic patients receiving empagliflozin after myocardial infarction, perfused boundary region, flow-mediated dilation, and global longitudinal strain were improved.\",\"PeriodicalId\":14831,\"journal\":{\"name\":\"JACC: Basic to Translational Science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":8.4000,\"publicationDate\":\"2024-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JACC: Basic to Translational Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jacbts.2024.08.003\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacbts.2024.08.003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Empagliflozin in Acute Myocardial Infarction Reduces No-Reflow and Preserves Cardiac Function by Preventing Endothelial Damage
Empagliflozin treatment before acute myocardial infarction mainly targets the endothelial cell transcriptome. Empagliflozin treatment before and after myocardial infarction decreased no reflow and microvascular injury, leading to reduced infiltration of inflammatory cells, reduced infarct size, and improved cardiac function in mice. In diabetic patients receiving empagliflozin after myocardial infarction, perfused boundary region, flow-mediated dilation, and global longitudinal strain were improved.
期刊介绍：
JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
